Drug Trial Radar · NCT05400265
Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor
Last checked: Nov 19, 2026Latest source record: Feb 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9
Actual
Start
Jul 26, 2022
Primary completion
Aug 31, 2023
Study completion Jan 31, 2024
Sponsor
- Lead sponsor
- Shanghai Henlius BiotechIndustry
- Sponsor type
- Industry
- First posted
- Jun 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a open-label, phase I, dose escalation clinical study to evaluate the safety and tolerability of HLX26 and HLX10 in the treatment of patients with advanced/metastatic solid tumors.
Conditions
- Adult Solid Tumor
Interventions
HLX26Drug
Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
HLX10Drug
Humanized Anti-Programmed Death-1 Monoclonal Antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLTTime frame: from day1 to day 21
- MTDTime frame: from day1 to day 21
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xuzhou Central Hospital
Xuzhou, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.